Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
106.3 USD | -0.95% | -1.24% | -3.46% |
Apr. 29 | Abbott's Dissolving Stent Gets FDA Approval For Arteries Below the Knee | MT |
Apr. 26 | Dexcom's profit beats estimates on strong glucose monitor demand | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.46% | 186B | |
-2.47% | 107B | |
-3.83% | 67.44B | |
+3.22% | 50.03B | |
+16.09% | 47.81B | |
+4.79% | 41.03B | |
+1.47% | 26.85B | |
+2.46% | 25.82B | |
-0.58% | 25.01B | |
+16.55% | 24.74B |
- Stock Market
- Equities
- ABT Stock
- News Abbott Laboratories
- Abbott Laboratories Raises Midpoint of 2024 Guidance After First-Quarter Beat